Bristol-Myers Squibb BMY Free cash flow yield
Free cash flow yield at other companies
Other financials
Where this comes from
Calculated from Bristol-Myers Squibb’s reported figures.
Based on trailing twelve months.
The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's free cash flow yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's free cash flow yield?
- Bristol-Myers Squibb (BMY) reported free cash flow yield of 9.6% in Q1 2026.
- How has Bristol-Myers Squibb's free cash flow yield changed year-over-year?
- Bristol-Myers Squibb's free cash flow yield decreased by 8.8% year-over-year, from 10.5% to 9.6%.
- What is the long-term trend for Bristol-Myers Squibb's free cash flow yield?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's free cash flow yield has grown at a 8.3% compound annual growth rate (CAGR), from 39.4% to 54.1%.
- What does free cash flow yield mean?
- The spendable cash the business throws off each year as a percentage of its market price.
- How do you interpret free cash flow yield?
- Higher yield can mean better value — you pay less for each dollar of cash generated. A useful sanity check against earnings-based multiples, which non-cash items can distort.
- How does free cash flow yield compare across companies?
- Comparable across cash-generative companies; less meaningful for firms in heavy-investment phases with temporarily negative FCF.